Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.33, $0.53 better than the analyst estimate of $1.80. Revenue for the quarter came in at $743.3 million versus the consensus estimate of $716.36 million.

GUIDANCE:

Charles River Laboratories sees FY2020 EPS of $7.75-$7.85, versus the consensus of $7.26.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.